12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

Phase 2

Completed

• Conditions: Parkinson's Disease

• Registration Number: NCT00456586
• Lead Sponsor: Kyowa Kirin, Inc.

Brief Summary

12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.

Detailed Description

A 12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.

Study Timeline

• Study Start: 2002-04
• Primary Completion: 2003-05
• Study Completion: 2003-06
• Study First Submitted: 2007-04-03
• Study First Submitted QC: 2007-04-03
• Study First Posted: 2007-04-05
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-23
• Last Update Posted: 2024-04-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

1. United Kingdom Parkinson's Disease Society brain bank diagnostic criteria (step 1 and 2).
2. Modified Hoehn and Yahr Scale II-IV in the OFF state.
3. Treated with levodopa/carbidopa for 1 year with a stable regimen for 4 weeks prior to randomization.
4. Taking at least 4 doses of levodopa (3 doses if at least 2 doses containing slow release formulation) per day with predictable end of dose wearing off.
5. Successfully completed Parkinson's disease patient diary training with at least 120 minutes of OFF time per day.
6. Stable regimen of other antiparkinson's disease medications for at least 4 weeks prior to randomization.
7. At least 30 years of age and able to give written informed consent.

Exclusion Criteria

1. Treatment with liquid levodopa/carbodopa within 4 weeks of randomization.
2. Treatment with MAO inhibitors except selegiline.
3. Treatment with centrally acting dopamine antagonists within 3 months (6 months for depot preparations), e.g., antipsychotic neuroleptics, metoclopramide, buspirone, amoxapine.
4. Neurosurgical surgery for Parkinson's disease.
5. Atypical parkinsonism or secondary parkinsonism variants.
6. Diagnosis of cancer or evidence of continued cancer within 5 years of enrollment or clinically significant illness of any organ system (e.g., ALT or AST > 1.5 times the upper limit of normal).
7. Mini-Mental Status Examination score of 25 or less.
8. History of drug or alcohol abuse or dependence within 2 years.
9. History of psychotic illness or seizures.
10. Current clinically relevant depression disorder.
11. History of neuroleptic malignant syndrome.
12. Pregnant or lactating females. Women of child-bearing potential must use reliable method of contraception.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To evaluate the safety and efficacy of 40 mg/day istradefylline for reducing OFF time in subjects with Parkinson's disease (PD) treated with levodopa/carbidopa.

Secondary Outcome Measures

Name	Time	Method
To establish the efficacy of 40 mg/day istradefylline for reducing motor symptoms and improving activities of daily living (ADL) in subjects with advanced PD treated with levodopa/carbidopa.

Trial Locations

Locations (1)

Contact Kyowa Pharmacuetical Inc.; 🇺🇸 Princeton, New Jersey, United States